News | May 30, 2023
Hikal posts FY23 PAT at Rs. 36 Cr
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Fully equipped labs with 75-member team set-up and made operational in <100 days
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
To enable company to be future-ready by tapping potential in CDMO space
Subscribe To Our Newsletter & Stay Updated
